CEO Thomas Schinecker emphasized that 2024 was an "excellent year," with overall group sales growing 7%, driven by 9% growth in the base business. Pharma and diagnostics segments both recorded 9% and ...
Health Care and Energy sectors outperform in 2025, with the Health Care Select Sector SPDR Fund ETF up 7% YTD, while Edwards Lifesciences lags. Despite a solid Q4 earnings beat, EW's shares remain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback